Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$16.76 -1.4%	$17.69	$13.53 ▼ $35.25	$1.69B	2.09	1.48 million shs	2.19 million shs
KNSA Kiniksa Pharmaceuticals International	$28.44 +1.8%	$25.99	$17.38 ▼ $30.69	$2.08B	0.06	514,199 shs	654,925 shs
TARS Tarsus Pharmaceuticals	$40.65 -1.0%	$45.09	$20.08 ▼ $57.28	$1.71B	0.83	700,683 shs	1.28 million shs
TRUU True Drinks	$0.09 -9.4%	$0.10	$0.00 ▼ $0.08	$448.04M	10.9	1.01 million shs	37,692 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	-1.76%	-0.42%	-30.20%	-26.94%
KNSA Kiniksa Pharmaceuticals International	0.00%	+0.49%	+5.76%	+21.49%	+52.82%
TARS Tarsus Pharmaceuticals	0.00%	-0.59%	-5.42%	-22.36%	+55.87%
TRUU True Drinks	0.00%	-10.08%	+7.97%	+55.61%	-37.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.9267 of 5 stars	4.5	1.0	0.0	0.0	1.5	2.5	0.6
KNSA Kiniksa Pharmaceuticals International	3.1708 of 5 stars	3.5	3.0	0.0	0.0	2.6	3.3	0.6
TARS Tarsus Pharmaceuticals	1.9141 of 5 stars	3.5	0.0	0.0	0.0	2.1	2.5	0.6
TRUU True Drinks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	190.87% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$38.80	36.43% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	64.00% Upside
TRUU True Drinks	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TRUU, KNSA, TARS, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
5/27/2025	TARS Tarsus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$72.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
5/5/2025	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$46.00 ➝ $51.00
5/2/2025	TARS Tarsus Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $84.00
4/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/16/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$34.00 ➝ $34.00
4/7/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/28/2025	BEAM Beam Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$42.00 ➝ $42.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	26.53	N/A	N/A	$8.86 per share	1.89
KNSA Kiniksa Pharmaceuticals International	$423.24M	4.90	N/A	N/A	$6.60 per share	4.31
TARS Tarsus Pharmaceuticals	$182.95M	9.33	N/A	N/A	$5.87 per share	6.93
TRUU True Drinks	$1.95M	229.76	N/A	N/A	($0.03) per share	-3.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	113.76	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.73	N/A	N/A	N/A	-44.91%	-39.72%	-25.74%	8/6/2025 (Estimated)
TRUU True Drinks	-$3.88M	$0.01	9.01	∞	N/A	-255.80%	N/A	-165.86%	N/A

Latest TRUU, KNSA, TARS, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRUU True Drinks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
TARS Tarsus Pharmaceuticals	0.21	5.57	5.54
TRUU True Drinks	N/A	0.01	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
KNSA Kiniksa Pharmaceuticals International	53.95%
TARS Tarsus Pharmaceuticals	90.01%
TRUU True Drinks	N/A

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
KNSA Kiniksa Pharmaceuticals International	53.48%
TARS Tarsus Pharmaceuticals	8.97%
TRUU True Drinks	18.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	38.25 million	Optionable
TRUU True Drinks	40	4.97 billion	N/A	Not Optionable

TRUU, KNSA, TARS, and BEAM Headlines

Recent News About These Companies

True Drinks (OTCMKTS:TRUU) Stock Crosses Above Fifty Day Moving Average - Here's Why

June 1, 2025 | marketbeat.com

Beer News: True Acts Of Aletruism / New “Indie Beer” Campaign

November 13, 2024 | americancraftbeer.com

How Much Alcohol Can You Drink a Week and Still Be Healthy?

November 13, 2024 | msn.com

Starbucks holiday menu: What's the healthiest drink? How much sugar, caffeine is in the seasonal beverages and other nutritional facts

November 9, 2024 | msn.com

Can You Drink Alcohol After Getting a COVID-19 Booster?

October 29, 2024 | health.com

It's True: Some Pizza Hut Locations Still Serve Alcohol

October 22, 2024 | yahoo.com

Review: True Story Finished Bourbon

October 21, 2024 | msn.com

Vitalizes Body and Mind.®

October 4, 2024 | redbull.com

7UP confirms limited release of ‘most overdue’ soda flavor: ‘Dream come true’

October 2, 2024 | msn.com

‘Diabetes in a cup!’ Dunkin worker reveals most ‘absurd’ drink he’s ever made — here’s what’s in it

September 21, 2024 | nypost.com

Seattle’s True Loves Drop a Funky New Single

August 31, 2024 | msn.com

Cannabis Beverage of the Week: Nowadays stands out in a crowded field of THC drinks

August 31, 2024 | msn.com

These alcoholic drinks can raise the risk of gout, a painful type of arthritis

August 30, 2024 | nypost.com

14 Drinks You Should Think Twice About Ordering At A Bar, According To A Master Mixologist

August 29, 2024 | yahoo.com

7 things you NEED to know about Prime Drinks (and the very different things the internet will tell you)

August 25, 2024 | bbc.co.uk

12 Unhealthiest Drinks You Should Think Twice About Ordering At A Bar

August 18, 2024 | msn.com

True Loaf Bakery gets starter from two local bakers

August 10, 2024 | msn.com

PD TRUE : STREAM IT OR SKIP IT?

August 6, 2024 | decider.com

10 Drinks People Fake Liking to Fit In

August 5, 2024 | msn.com

16 Best Summer Cocktails for a Hot Weather Buzz

July 26, 2024 | esquire.com

What is ‘fluffy Coke’? Sugary drink dubbed ‘diabetes in a cup’ is the hottest beverage of the summer

July 23, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRUU, KNSA, TARS, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$16.76 -0.23 (-1.35%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$16.68 -0.09 (-0.51%)

As of 06/20/2025 07:18 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.44 +0.51 (+1.83%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$28.46 +0.01 (+0.05%)

As of 06/20/2025 04:13 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Tarsus Pharmaceuticals NASDAQ:TARS

$40.65 -0.42 (-1.02%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$40.64 -0.01 (-0.02%)

As of 06/20/2025 05:52 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

True Drinks OTCMKTS:TRUU

$0.09 -0.01 (-9.45%)

As of 06/20/2025

True Drinks Holdings, Inc. markets and distributes nutritional supplement drinks. The company sells Bazi All Natural Energy, a liquid nutritional supplement drink through drinkbazi.com. It also formulates products containing CBD; and produces and distributes vapor products in approximately 90 countries. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time